June 24, 2008

Opexa is reporting 73% of patients remained relapse-free at two years in their Tovaxin trial. It's a small trial (22 people), but the results look promising.

More positive results reported on immunosuppressive therapy followed by autologous haematopoietic stem cell transplantation. It seems to be getting safer and "rebooting the immune system" may become a more viable treatment in MS.